Journal article icon

Journal article

B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity

Abstract:
This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20+ and CD27+ B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (p = 0.016) and from baseline to attack (p = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/acn3.52171

Authors


More by this author
Role:
Author
ORCID:
0000-0002-6140-5584
More by this author
Role:
Author
ORCID:
0000-0002-6378-0070
More by this author
Role:
Author
ORCID:
0000-0002-8672-8419
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Clinical Neurosciences
Oxford college:
Corpus Christi College
Role:
Author
ORCID:
0000-0002-7667-9748
More by this author
Role:
Author
ORCID:
0000-0002-3346-1394


More from this funder
Funder identifier:
https://ror.org/03x94j517
Grant:
MR/V007173/1
More from this funder
Funder identifier:
https://ror.org/00exehz38


Publisher:
Wiley
Journal:
Annals of Clinical and Translational Neurology More from this journal
Volume:
11
Issue:
10
Pages:
2792-2798
Place of publication:
United States
Publication date:
2024-09-02
Acceptance date:
2024-07-15
DOI:
EISSN:
2328-9503
Pmid:
39222408


Language:
English
Pubs id:
2026541
Local pid:
pubs:2026541
Deposit date:
2025-02-05

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP